Why is Aspira Pathlab falling/rising?

As of 07-Jul, Aspira Pathlab & Diagnostics Ltd is experiencing a decline in its stock price, currently at 54.62, reflecting a decrease of 1.1 or 1.97%. Today's performance indicates that the stock has underperformed its sector by 2.26%, and it has not traded on one day out of the last twenty, suggesting erratic trading behavior. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite positive financial results over the last four quarters, including significant growth in profit after tax and net sales, the stock's recent performance has been overshadowed by a 5.83% decline over the past week and an 8.20% drop year-to-date.
In the broader market context, Aspira Pathlab's short-term performance is notably worse than the benchmark, with a 1-week return of -5.83% compared to the Sensex's slight decline of 0.20%. While the stock has generated a substantial return of 75.12% over the past year, significantly outperforming the market's 1.74%, concerns about weak long-term fundamental strength and a poor EBIT to interest ratio may be contributing to investor hesitance. The stock's liquidity issues, highlighted by a drastic drop in delivery volume, further complicate its market position, leading to a cautious outlook among investors.